Advancement in vaccination against Newcastle disease: recombinant HVT NDV provides high clinical protection and reduces challenge virus shedding with the absence of vaccine reactions.
about
Modulation of systemic and mucosal immunity against an inactivated vaccine of Newcastle disease virus by oral co-administration of live attenuated Salmonella enterica serovar Typhimurium expressing chicken interleukin-18 and interferon-α.Identification of non-essential loci within the Meleagrid herpesvirus 1 genome.Presence of Vaccine-Derived Newcastle Disease Viruses in Wild Birds.Characterisation of genotype VII Newcastle disease virus (NDV) isolated from NDV vaccinated chickens, and the efficacy of LaSota and recombinant genotype VII vaccines against challenge with velogenic NDV.Virus-like particle vaccine confers protection against a lethal newcastle disease virus challenge in chickens and allows a strategy of differentiating infected from vaccinated animalsPair-epitopes vaccination: enabling offspring vaccination in the presence of maternal antibodies.Continuous cell lines from the Muscovy duck as potential replacement for primary cells in the production of avian vaccines.Characterization of two recombinant HVT-IBD vaccines by VP2 insert detection and cell-mediated immunity after vaccination of specific pathogen-free chickens.Diatoms and diatomaceous earth as novel poultry vaccine adjuvants.Genomic deletions and mutations resulting in the loss of eight genes reduce the in vivo replication capacity of Meleagrid herpesvirus 1.Anti-NDV activity of baicalin from a traditional Chinese medicine in vitro.Quantification of rHVT-F genome load in feather follicles by specific real-time qPCR as an indicator of NDV-specific humoral immunity induced by day-old vaccination in SPF chickens.Pathological and molecular investigation of velogenic viscerotropic Newcastle disease outbreak in a vaccinated chicken flocksDiagnostic and Vaccination Approaches for Newcastle Disease Virus in Poultry: The Current and Emerging Perspectives
P2860
Q35594410-6ED77E0B-DA6A-4017-9EC4-A80890071463Q35755336-5D4947FD-CED7-495B-B034-A8A6607EB35AQ36132147-8E2A5D69-0763-4786-892C-6D087AAD7BAAQ36431309-BBA2F230-A1D4-40FF-A333-CC0421109F21Q38320531-D1C026B5-FA44-45D2-BB69-D41DE4092B80Q38402961-830652BD-BD8A-4671-9C09-700B0C001C8BQ38799241-5BAFA7B4-BAD4-42A4-A40C-46543F114500Q40431501-4C7E8D71-FBFD-4DDA-A50C-CA8C8EBB31A3Q40644104-1A95E2CF-903C-40F8-8A60-B523D60CD41AQ40763156-B08C02C5-F218-4A15-998A-4F1C84DB2D8FQ40781910-27BDAFED-CC7B-46BC-8E5B-B5A56A6226A5Q41427446-6D2E7AFD-8433-4980-99D9-7FDC145E132AQ56424990-64324E40-5AE2-4A8F-BF05-86EE79C931FFQ58800131-550A21A2-99A3-4F5F-B8FF-86FFA80F0828
P2860
Advancement in vaccination against Newcastle disease: recombinant HVT NDV provides high clinical protection and reduces challenge virus shedding with the absence of vaccine reactions.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Advancement in vaccination aga ...... absence of vaccine reactions.
@en
type
label
Advancement in vaccination aga ...... absence of vaccine reactions.
@en
prefLabel
Advancement in vaccination aga ...... absence of vaccine reactions.
@en
P2093
P1433
P1476
Advancement in vaccination aga ...... absence of vaccine reactions.
@en
P2093
P304
P356
10.1637/9935-091511-REG.1
P577
2012-06-01T00:00:00Z